Update shared on 09 Dec 2025
Analysts have nudged their price target for Terveystalo Oyj to EUR 11.30, reflecting largely unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples that continue to support a steady, fairly valued outlook.
What's in the News
- Terveystalo and Nightingale Health signed a new agreement that deepens their strategic partnership and extends Nightingale's blood analysis service to all Terveystalo customer segments, beyond its existing use in occupational health checks for over 200,000 Finns (Key Developments)
- The expanded Nightingale collaboration aims to advance innovative healthcare by using a single blood sample to provide disease risk assessments for multiple chronic diseases, now integrated more broadly into Terveystalo's service offering (Key Developments)
- Terveystalo reaffirmed its earnings guidance for 2025, stating that it expects earnings per share to grow on average by 10 percent per year, with faster EPS growth in 2025 as fewer items affecting comparability are anticipated (Key Developments)
Valuation Changes
- Fair Value: unchanged at €11.30 per share, indicating no reassessment of the company’s intrinsic value.
- Discount Rate: stable at 5.67 percent, suggesting no change in perceived risk or required return.
- Revenue Growth: effectively unchanged at about 1.97 percent, implying a steady outlook for top line expansion.
- Net Profit Margin: flat at approximately 8.96 percent, reflecting consistent expectations for profitability.
- Future P/E: unchanged at about 13.57x, indicating stable assumptions for the company’s forward earnings multiple.
Have other thoughts on Terveystalo Oyj?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.